semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hypophosphatasia Patients or their legal representative must provide written informed consent or, if applicable, qualify for waiver of consent Patients must have a pre-established clinical diagnosis of HPP, as indicated by one or more of the following Serum alkaline phosphatase (ALP) below the age-adjusted normal range Plasma PLP at least twice the upper limit of normal (no vitamin B6 administered for at least 1 week prior to determination) Evidence of osteopenia or osteomalacia on skeletal radiographs Genetic analysis fof the ALPL gene  Any patient without confirmation of clinical diagnosis of HPP
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Prostatic Hyperplasia Male patients (45 years of age or older) diagnosed with benign prostatic hyperplasia Patients with a total score on the AUA Symptom Index for BPH of at least 13 points at each of the three initial visits (Visits 1, 2 and 3) A baseline prostate specific antigen (PSA) of ≤ 4.0 ng/ml Patients who are able to give written informed consent before performing screening examinations or tests Patients being judged by the investigator to be reliable and able to follow protocol procedures (including the return visits schedule), and cooperate in the completion of tests related to safety and efficacy  Patients with a history of an allergy to alpha blockers, alpha/beta blockers or patients who have had a "first dose hypotensive episode" upon starting therapy with an alpha blocker Patients who are currently being treated or who, in the last 3 months, have been treated with finasteride Participated in an investigational drug study within 4 weeks prior to starting placebo phase Patients taking medication in the following classes and unable to discontinue them at least two weeks before the study and for the duration of the study Alpha adrenergic blocking agents Alpha adrenergic agonists Drugs with anticholinergic activity (including antihistamines) Antispasmodics Parasympathomimetics and cholinomimetics Peripheral or central neurologic disease including, but not limited to, transient ischemic attacks, stroke, dementia, multiple sclerosis, spinal cord injury, recurrent episodes of dizziness, vertigo, or loss of consciousness, clinically evident diabetic neuropathy, brain and/or spinal cord tumors
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Prostate Hyperplasia Phase I Adult men, 45 years of age or older, diagnosed with acute urinary retention due to BPH Patients who have never taken alpha-blockers or discontinued taking alpha-blockers 72 hours or more prior to entrance into this study Patients that have been treated with an indwelling urethral catheter as treatment for acute urinary retention (AUR) due to BPH Patients must be judged by the investigator to be reliable and willing to comply with all tests and examinations stipulated in the protocol All patients must be willing to give meaningful, written, informed consent prior to participation in the trial, in accordance with regulatory requirements. Patients must also have sufficient understanding to communicate effectively with the investigator Phase II Patients who voided spontaneously, at least 100 mL and a post-void residual volume of ≤ 300 mL, at Visit 2  Phase I Patients diagnosed with a symptomatic/active urinary tract infection (UTI) or an abnormal urine culture at baseline or 2 or more UTIs within the last six months. An abnormal urine culture was defined as A bacterial colony count of greater than or equal to 100,000 CFU/mL or A bacterial colony count of greater than or equal to 100 CFU/mL of a known urinary pathogen in a symptomatic patient Patients that have a distended bladder volume greater than 1.5 liters (1500 ml) of retention as measured by initial catheter urine volume Patients with history of sexually transmitted disease within last two years Patients with active genital herpes disease whose urinary function was impacted due to the disease Patients who have a history of mechanical outlet obstruction excluding BPH (i.e., bladder neck contracture or stricture, bladder tumor, or bladder calculi) Patients with urethral stricture disease Patients with a history of bladder, prostate, or urethral surgery in the last three months
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Chronic Obstructive Pulmonary Disease Current or former smokers (> 10 pack years) or biomass exposure years of age Clinical diagnosis of COPD Post-bronchodilator FEV1 < 70% predicted Post bronchodilator FEV1/FVC ratio < 0.7  Life expectancy of less than 12 months Exacerbation or respiratory infection within 4 weeks prior to randomisation Patient is taking and requires maintenance oral corticosteroids Patient is on domiciliary oxygen There has been previous pulmonary resection Previous sensitivity to, or intolerance of theophylline Coexistent illness precluding participation in the study (epilepsy, chronic liver disease, unstable cardiovascular disease, diabetes, active malignancy) Inability to complete quality of life questionnaire Concomitant major illness that would interfere with visits, assessments and follow-up Have evidence of chronic liver disease, or transaminase or gamma-glutamyltransferase (GGT) elevation > 1.5 x upper limit of normal (ULN)
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cough Dyspnea Wheezing Presenting to the Emergency Department with cough, wheezing and/or dyspnea (shortness of breath) Referred for CXR and/or CT scan  Life threatening medical condition requiring immediate treatment Unable to sit up for a chest ultrasound Unable to consent Pregnant Unable to speak, read and write in English
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Mental Illness aged 18-60 years, able to understand Cantonese/Mandarin having the first-onset of the mental illness (psychotic and mood disorders) within the past six months and new referral or contact with mental healthcare services presenting at least moderate to high levels of psychiatric symptoms (i.e., Brief Psychiatric Rating Scale score of >25 out of 126 and/or Chinese version of the Beck's Depression Inventory-II scores of >10 out of 63); and indicating no history and low risk of suicide and self-harm  receiving other psychosocial interventions organized by the clinics or other healthcare organizations; and being classified as the highest priority of psychiatric consultation and treatment (i.e., starting their treatment and care plan with their attending psychiatrist and clinic nurse within one week). [Note: For SPBB study, the of the participants those who are: Hong Kong Chinese residents, aged 18-64; taking care of and living with a family member primarily diagnosed with one psychotic disorder in the past 12 months psychosis will be recruited; able to read and understand Cantonese/Mandarin; and perceived a moderate to high burden of care (measured by Family Burden Interview Schedule (>20 out of 50 scores) of family caregivers those: received or are receiving another family intervention; are having cognitive impairment or learning disability; and/or presented with a recent personal history of a serious mental illness or medical disease that may adversely affect their ability to participate in the intervention.]
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 0.083-17.0,  Chronic Illness Children ages 0 to 17 years old who are enrolled in the Pediatric Medical Home Program at UCLA English and Spanish-speaking only  Children older than 17 years old who are enrolled in the Pediatric Medical Home Program Non-English and Non-Spanish speakers
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  COPD Exacerbation Current or past cigarette smoking history of >/= 10 pack-years FEV1/FVC ratio </= 70% Known diagnosis of COPD Current hospitalization for a primary diagnosis of acute exacerbation of COPD Must be able to understand and willing to sign an informed consent document  On a ventilator or mask ventilation Allergy or contraindication to Formoterol use Marked QTc prolongation (> 450 ms) Liver cirrhosis or chronic renal insufficiency (serum creatinine > 2 mg/dL) Atrial fibrillation with rapid ventricular response (heart rate > 110 bpm) or ventricular arrhythmia (frequent PVCs, ventricular tachycardia) Acute myocardial infarction within 12 weeks of patient study registration Known pulmonary embolism Known or suspected lung cancer Known neuromuscular disease, stroke with residual hemiparesis, or untreated Parkinsonism Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e., oral contraceptives, intrauterine devices, diaphragm, or sub dermal implants)
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-70.0,  Chronic Obstructive Pulmonary Disease (COPD) Patients aged 40-70 years old; Patients with pulmonary function test of FEV1/FVC < 70% and FEV1%pred < 50%; Patients in a clinically stable state; Patients who signed informed consent  Patients with signs of an airway infection; Patients with an acute exacerbation during the previous 4 weeks; Patients with giant bulla(≥3cm in diameter); Patients with recent upper abdominal surgery; Patients with one or more of the following diseases: esophageal cancer, reflux esophagitis, severe obstructive sleep apnea (apnea hypopnea index>15/hr), neuromuscular disease, or significant heart failure; Patients with poor compliance
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pulmonary Disease, Chronic Obstructive Subject must be 18 years of age or older Subject has been diagnosed as having asthma and/or COPD Informed consent is required for independent sites initiating this protocol
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Inflammatory Disorder of the Respiratory Tract Chronic Obstructive Pulmonary Disorder Informed consent Males following contraception requirements, and agree not to donate sperm during study lead ECG within normal range and no clinically significant abnormality Screening Holter report (minimum 18 hours) recording that is able to be evaluated for rhythm analysis which shows no abnormality which indicates a significant impairment of subject safety or which may significantly impair interpretation Capable of complying with all study restrictions and procedures including ability to use the study nebuliser correctly Body weight ≥50 kg Negative for HIV, HBV and HCV Negative cotinine tests prior to randomisation. Additional Healthy Subjects (Parts A and B) only Males aged 18 and 50 years  Respiratory tract infection (both upper and lower) treated with antibiotics in last 12 weeks Clinically significant abnormal values for safety laboratory tests or physical examination History or suspected history of drug or alcohol abuse within the past 5 years Known allergy to the study drug or any of the excipients of the formulation Donated blood or blood products or had substantial loss of blood (more than 500 mL) in last 4 weeks or intention to donate blood or blood products during the study Received an experimental drug or used an experimental medical device within 3 months or within a period less than 5 times the drug's half-life, whichever is longer Pre-planned surgery or procedures that would interfere with the conduct of the study Employee of the Investigator or study site or family members of the employees or the Investigator History of regular alcohol consumption within last 6 months Unable or unwilling to comply fully with the study protocol
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  COPD Established diagnosis of COPD with FEV1 <60% predicted FEV1/FVC <70% and <+15% FEV1 response to bronchodilator Patients of both genders will be included IRB approved written informed consent will be obtained from each subject  Recent (<1 month) exacerbation of COPD, 2. Known hypersensitivity to beta agonists, theophylline, steroids, or roflumilast. 3. Current or recent (<2 weeks) treatment with oral steroids, theophylline or other methylxanthines, or roflumlast. 4. Diagnosis or history of asthma, uncontrolled hypertension, or congestive heart failure. 5. History of Cardiac arrhythmia 6. History of seizures. 7. History of Liver disease 8. Gastrointestinal disease, including history of peptic ulcer disease. 9. Current infection or antibiotic treatment. 10. History of depression or psychiatric disease
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  COPD Stable symptomatic patients with GOLD grade 1B mild COPD at least 50 years of age a cigarette smoking history ≥20 pack-years a Baseline Dyspnea Index focal score ≤9 post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥80 %predicted and an FEV1/forced vital capacity (FVC) ratio <0.7 and < lower limit of normal  clinically significant comorbidities contraindications to exercise testing history/clinical evidence of asthma body mass index <18.5 or >30 kg/m2 use of supplemental oxygen
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 35.0-50.0,  COPD **Inclusion COPD case Subjects between 35 and 50 years Post-bronchodilator spirometry with FEV1/FVC <70% Smoker or ex-smoker with total cumulative exposure > 10 pack-years Smoking control Subjects between 35 and 50 years Post-bronchodilator spirometry with FEV1/FVC >=70% Smoker or ex-smoker with total cumulative exposure> 10 pack-years  For cases Chronic inflammatory diseases including autoimmune diseases under treatment HIV Active cancer Cystic or saccular bronchiectasis Conditions that may interfere with follow-up: frequent change of residence, psychiatric disorders, dementia… For controls Chronic inflammatory diseases including autoimmune diseases under treatment HIV Active cancer Chronic respiratory diseases